Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
Cue Biopharma reported Q1 2026 revenue of $5.7 million, a massive increase from $0.4 million in the prior year, driven by a collaboration with Boehringer Ingelheim. The company narrowed its net loss to $5.2 million from $12.3 million, aided by lower R&D spend and a gain on lease termination. The company appointed Shao-Lee Lin as President and CEO, bringing 25 years of immunology experience to lead the transition into a clinical-stage company. Lin highlighted that the recent financing extends the cash runway to support key clinical milestones for assets CUE-221 and CUE-401 in the second half of 2026.
Key figures
- Revenue
- 5686000
- Revenue Yoy
- 1248%
- Rd expense
- 6897000
- G and a expense
- 4152000
- Milestone payment
- 7500000
- Weighted avg shares
- 4807494
- Cash and equivalents
- 16379000
- Private placement proceeds
- 30000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.